(Q38123737)

29 August 2017

title

Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy (English)

1 reference

29 August 2017

1 reference

1

Emma D Deeks

1 reference

29 August 2017

publication date

1 September 2013

1 reference

Clinical Drug Investigation

29 August 2017

published in

1 reference

29 August 2017

volume

33

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

689-697

1 reference

Guidelines for prevention of NSAID-related ulcer complications

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Gastrointestinal and Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Coming to terms with nonsteroidal anti-inflammatory drug gastropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

DUEXIS(®) (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Ibuprofen: pharmacology, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Ag

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Endoscopic ulcers are neither meaningful nor validated as a surrogate for clinically significant upper gastrointestinal harm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0113-X

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

12 December 2020

Editorial: single-tablet ibuprofen/double-dose famotidine for reduction of gastric and duodenal ulcers (REDUCE Trials): what can be reduced?

1 reference

12 December 2020

Single-tablet double-dose famotidine plus ibuprofen decreases endoscopic upper GI ulcers compared with ibuprofen alone

1 reference

12 December 2020

Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction

1 reference

12 December 2020

10.1007/S40261-013-0113-X

Identifiers

DOI

1 reference

29 August 2017

1 reference